STRIDES PHARMA SCIENCE LTD Q2 RESULTS
Coronavirus crisis: It's time for India Inc to create opportunities
While India may start seeing disruption in the next few weeks, the crisis could also seed opportunities.
Strides Pharma Science Q3 net declines 69% to Rs 92 crore
The consolidated income of the company increased to Rs 744.66 crore in the Oct-Dec ...
Bayer CropScience Q2 profit rises slightly to Rs 170 crore
Total income rose to Rs 1,356.5 crore against Rs 1,249.1 crore.
Our drug Ranitidine is safe: Strides Pharma
Ranitidine is a commonly prescribed medicine for countering acidity and is on the WHO’s Model List of Essential Medicines. In India, a host of companies including GalxoSmithKline, JB Chemicals, Cadila Pharma, Zydus Cadila, Dr Reddy’s and Sun Pharmaceuticals sell over 180 versions of the drug. Strides Pharma is likely to resume drug sale, following the report.
20 firms turned around in Q2! Are they compelling ‘buy’ ideas now?
Seventeen of these 20 stocks posted up to 51 per cent YoY rise in net sales for the quarter.
Jubilant Life Q2 profit up 19% to Rs 249 cr; firm to demerge Life Science Ingredients biz
Total revenue from operations stood at Rs 2,265.93 crore for the quarter under consideration.
Strides Pharma relaunches Ranitidine tablets in US
The company had suspended sales of its generic Ranitidine tablets after the USFDA found contamination in some Ranitidine tablets sold by various companies with potentially cancer causing impurities, NDMA. Strides said now the drug meets the limits prescribed by the US drug regulator.
Strides Pharma shares plunge 8% as company suspends sales of ranitidine tablets in US
On the National Stock Exchange, it cracked 7.94 per cent to close at Rs 302.60.
Multibaggers of past decade, solid show in Q2, but stocks down 50%: Get the cue
Many analysts look positive on them. Good case to take a serious look at these names?
Stocks in the news: Gati, Bharti Airtel, Alembic Pharma, Aster DM and DHFL
GMR Infra has raised Rs 2,000 crore debt through nonconvertible debentures from Tata Sons.
Why S Naren is betting on small and midcap stocks in power and infra
Smallcaps have better absolute return potential in long term over midcaps & largecaps.
Biocon number six in top 10 Global Biotech Employers ranking for 2019
Biocon continues to be the only company from Asia to feature on the prestigious US-based 'Science' magazine's annual 'Science Careers Top 20 Employers' list, since its debut in 2012.
Strides Pharma Science Q3 profit at Rs 296 crore
Consolidated revenue from operations of the company stood at Rs 794.50 crore.
Buy Strides Pharma Science, target Rs 590: Motilal Oswal Securities
Buy Strides Pharma Science at a price target of Rs 590.
There is a very big opportunity in PSU stocks: Rakesh Jhunjhunwala
I have never seen such volatility, but selectively the market has bottomed out.
Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service